Market Segmentation:
- By Therapy Type
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Tyrosine Kinase Inhibitors (TKIs)
- Cytokine Therapy
- Others (e.g., Oncolytic Viruses, Cancer Vaccines)
- By Mechanism of Action
- PD-1/PD-L1 Inhibition
- CTLA-4 Inhibition
- PI3K/AKT/mTOR Pathway Inhibition
- MAPK Pathway Inhibition
- Angiogenesis Inhibition
- DNA Damage Response Inhibition
- Others (e.g., Immunomodulatory, Epigenetic Modulation)
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the PD-1 Resistant Head and Neck Cancer (HNC) industry is US$ 120 million.
Rising incidence of head and neck cancers, Increasing cases of drug resistance, Unmet clinical needs for advanced or metastatic cases, Promising clinical data and therapeutic advancements
High treatment costs, Stringent regulatory approval processes, Limited clinical data and uncertainty, Adverse effects of therapies
The leading component segment in the PD-1 Resistant Head and Neck Cancer (HNC) Market is the antibody-drug conjugates (ADCs) segment, which targets specific proteins overexpressed in cancer cells.
The major players operating in the PD-1 Resistant Head and Neck Cancer (HNC) Market include AstraZeneca, Merck & Co., Bristol-Myers Squibb, Regeneron Pharmaceuticals, Eli Lilly and Company, Novartis, Pfizer, Roche, Sanofi, GlaxoSmithKline, Johnson & Johnson, Amgen, AbbVie, Bayer, Gilead Sciences, Incyte Corporation, Ono Pharmaceutical, Daiichi Sankyo, Astellas Pharma, and Takeda Pharmaceutical.
The North America region is expected to lead the PD-1 Resistant Head and Neck Cancer (HNC) Market, with a projected CAGR of 41.5% and a market size of US$ 1,928.6 million by 2031.
Rising incidence of head and neck cancers, Increasing cases of drug resistance, Unmet clinical needs for advanced or metastatic cases, Promising clinical data and therapeutic advancements